Using increased fluid intake to improve kidney health in children with E. coli infections
Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial
This study is looking at whether giving kids more fluids early on when they have infections from a type of E. coli can help protect their kidneys and prevent serious problems, and it’s for children who are dealing with these infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Calgary NIH-funded |
| Lab location | 1 site (Calgary, Canada) |
| Project ID | NIH-10914066 on NIH RePORTER |
What this research studies
This research investigates the effects of hyperhydration, or increased fluid intake, on kidney outcomes in children suffering from infections caused by Shiga toxin-producing E. coli (STEC). The study aims to determine if administering more fluids early in the course of the infection can protect the kidneys and prevent serious complications like hemolytic uremic syndrome (HUS). By comparing this approach to traditional fluid management strategies, the researchers hope to find a more effective treatment for affected children. Participants will be monitored closely to assess kidney function and overall health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old who have been diagnosed with a STEC infection.
Not a fit: Patients who are older than 11 years or those who do not have a STEC infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved kidney health and reduced long-term complications for children infected with STEC.
How similar studies have performed: Previous smaller studies have not shown benefits with similar approaches, making this research a novel attempt to improve outcomes.
Where this research is happening
Calgary, Canada
- University of Calgary — Calgary, Canada (Active)
Researchers
- Principal investigator: Freedman, Stephen Bradley — University of Calgary
- Study coordinator: Freedman, Stephen Bradley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.